omniture
RECBIO

Latest News

Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project

TAIZHOU, China, March 27, 2024 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (hereafter refer...

2024-03-27 11:24 798

Jiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress

TAIZHOU, China, March 21, 2024 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announc...

2024-03-21 00:22 2716

Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines

TAIZHOU, China, Dec. 29, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", t...

2023-12-29 12:33 1981

Recbio appeared at the 14th China (Taizhou) International Pharmaceutical Fair

TAIZHOU, China, Oct. 24, 2023 /PRNewswire/ -- From October 19 to 22, the 14th China (Taizhou) Inter...

2023-10-24 13:39 1424

Recbio signed a strategic cooperation agreement with Zimbabwe National Biotechnology Administration and ICGEB China Regional Research Centre

TAIZHOU, China, Oct. 10, 2023 /PRNewswire/ -- On October 8, 2023, Dr. Deckster Tonny SAVADYE, CEO o...

2023-10-10 13:54 3752

Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report and latest progress

TAIZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announce...

2023-08-28 11:08 2456

Acceptance Of Clinical Trial Application For The Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China And Overseas Clinical Trial Progress

TAIZHOU, China, July 27, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Board") is p...

2023-07-27 10:57 3742

Inclusion of Recbio In the MSCI China Small Cap Index

TAIZHOU, China, May 17, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", to...

2023-05-17 14:01 5432

Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia

TAIZHOU, China, March 21, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", ...

2023-03-21 13:59 2459

Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610

TAIZHOU, China, Feb. 13, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", t...

2023-02-13 15:02 3349

Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines

TAIZHOU, China, Dec. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", t...

2022-12-19 13:53 2033

Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine

TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", t...

2022-12-14 15:17 3849

Jiangsu Recbio Technology Co., Ltd. Increases Production For The First Phase Of Manufacturing Facility With A Maximum Annual Output Of 20 Million Doses Of Recombinant HPV 9-Valent Vaccine

TAIZHOU, China, Nov. 21, 2022 /PRNewswire/ --  (the "Company", together with its subsidiaries, the ...

2022-11-21 16:07 2351

Update on overseas clinical trials progress of novel adjuvant COVID-19 vaccine ReCOV

TAIZHOU, China, Nov. 8, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", to...

2022-11-08 15:17 2015

Acceptance Of The Application For Clinical Trial Of Recbio Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine

TAIZHOU, China, Oct. 28, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", t...

2022-10-28 11:10 2868

Recbio Announces Interim results for the Fiscal Year 2022 and Company Progress

* The nine-valent HPV vaccine and other blockbuster varieties have been advanced efficiently. *...

2022-08-29 13:08 3149

Completion Of Subject Enrollment And Vaccination For The Comparative Study Between ReCOV And mRNA Vaccines

TAIZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", t...

2022-08-19 11:29 2058

Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine

TAIZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", to...

2022-08-10 16:06 2351

Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines

TAIZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", tog...

2022-08-03 13:09 2738
12